AI Article Synopsis
- - The text discusses a rare case of sarcomatoid melanoma, a type of malignant melanoma, where a patient had a metastatic giant tumor on the arm which was surgically removed.
- - Genetic testing revealed a BRAF V600E mutation, leading to the prescription of a BRAF/MEK inhibitor therapy as the first line treatment.
- - The patient achieved a complete response to the treatment with no side effects and was able to maintain full mobility and independence, suggesting the importance of BRAF mutation testing for certain melanoma patients.
Article Abstract
Sarcomatoid melanoma is an extremely rare pattern of malignant melanoma, and only few cases have been described throughout the literature. We herein report a case of a patient with newly diagnosed, metastatic giant sarcomatoid melanoma of the arm. The patient underwent surgical removal of the huge mass, and NGS sequencing demonstrated BRAF V600E mutation. In view of histological, immunohistochemical and molecular findings, a combined BRAF/MEK inhibitor (BRAF/MEK-i) therapy was prescribed as first line treatment. A complete response (over one year) to targeted therapy was obtained, and no adverse events have been reported. The patient maintained a full range of shoulder and elbow movements, and she is able to live independently and resume her daily activities. We therefore recommend that all patients with undifferentiated melanomas, sarcomatoid cutaneous malignancies or other mesenchymal tumours, should undergo BRAFV600E mutation testing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456614 | PMC |
| http://dx.doi.org/10.18632/oncotarget.27701 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!